Prevalence and disease burden of chronic kidney disease

JC Lv, LX Zhang - Renal fibrosis: mechanisms and therapies, 2019 - Springer
Chronic kidney disease (CKD) has been recognized as a leading public health problem
worldwide. The global estimated prevalence of CKD is 13.4%(11.7–15.1%), and patients …

Chronic kidney disease

AS Levey, J Coresh - The lancet, 2012 - thelancet.com
Chronic kidney disease is a general term for heterogeneous disorders affecting kidney
structure and function. The 2002 guidelines for definition and classification of this disease …

[HTML][HTML] The contribution of chronic kidney disease to the global burden of major noncommunicable diseases

WG Couser, G Remuzzi, S Mendis, M Tonelli - Kidney international, 2011 - Elsevier
Noncommunicable diseases (NCDs) are the most common causes of premature death and
morbidity and have a major impact on health-care costs, productivity, and growth …

Evolving importance of kidney disease: from subspecialty to global health burden

KU Eckardt, J Coresh, O Devuyst, RJ Johnson… - The Lancet, 2013 - thelancet.com
In the past decade, kidney disease diagnosed with objective measures of kidney damage
and function has been recognised as a major public health burden. The population …

Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis

G Musso, R Gambino, JH Tabibian, M Ekstedt… - PLoS …, 2014 - journals.plos.org
Background Chronic kidney disease (CKD) is a frequent, under-recognized condition and a
risk factor for renal failure and cardiovascular disease. Increasing evidence connects non …

Discovery and prioritization of variants and genes for kidney function in> 1.2 million individuals

KJ Stanzick, Y Li, P Schlosser, M Gorski… - Nature …, 2021 - nature.com
Genes underneath signals from genome-wide association studies (GWAS) for kidney
function are promising targets for functional studies, but prioritizing variants and genes is …

[PDF][PDF] Extrahepatic complications of nonalcoholic fatty liver disease

MJ Armstrong, LA Adams, A Canbay, WK Syn - Hepatology, 2014 - Wiley Online Library
Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, and is
strongly associated with the metabolic syndrome. In the last decade, it has become apparent …

Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials

X **e, Y Liu, V Perkovic, X Li, T Ninomiya… - American Journal of …, 2016 - Elsevier
Background There is much uncertainty regarding the relative effects of angiotensin-
converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) in …

Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis

A Mantovani, G Zaza, CD Byrne, A Lonardo, G Zoppini… - Metabolism, 2018 - Elsevier
Background Recent studies examined the prognostic impact of nonalcoholic fatty liver
disease (NAFLD) on the risk of incident chronic kidney disease (CKD). However, the extent …

Biomarkers of renal function, which and when?

ME Wasung, LS Chawla, M Madero - Clinica chimica acta, 2015 - Elsevier
Purpose of the review Acute kidney injury (AKI) and chronic kidney disease (CKD) are
conditions that substantially increase morbidity and mortality. Although novel biomarkers are …